Doximity (NYSE:DOCS) Rating Lowered to Hold at Barclays

Doximity (NYSE:DOCS) was downgraded by investment analysts at Barclays from a “strong-buy” rating to a “hold” rating in a report released on Thursday,Zacks.com reports.

Several other equities research analysts have also recently commented on the company. BTIG Research cut Doximity from a “buy” rating to a “neutral” rating in a research note on Thursday. Freedom Capital raised Doximity to a “strong-buy” rating in a research note on Tuesday, March 17th. Mizuho decreased their target price on Doximity from $34.00 to $26.00 and set a “neutral” rating for the company in a research note on Thursday. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $18.00 target price (down from $32.00) on shares of Doximity in a research note on Thursday. Finally, JPMorgan Chase & Co. decreased their target price on Doximity from $33.00 to $28.00 and set a “neutral” rating for the company in a research note on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and fourteen have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $30.62.

Doximity Stock Up 5.1%

NYSE DOCS opened at $18.93 on Thursday. The business’s 50 day simple moving average is $23.94. Doximity has a one year low of $17.15 and a one year high of $76.51. The firm has a market capitalization of $3.50 billion, a PE ratio of 19.12, a P/E/G ratio of 1.28 and a beta of 1.36.

Doximity declared that its Board of Directors has initiated a stock repurchase program on Thursday, February 5th that permits the company to repurchase $500.00 million in outstanding shares. This repurchase authorization permits the company to buy up to 8% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s board believes its shares are undervalued.

Insider Activity at Doximity

In other Doximity news, insider Siddharth Sitaram sold 2,427 shares of the stock in a transaction that occurred on Friday, April 10th. The stock was sold at an average price of $21.09, for a total value of $51,185.43. Following the transaction, the insider owned 86,705 shares in the company, valued at approximately $1,828,608.45. This represents a 2.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kira Scherer Wampler sold 9,000 shares of the stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $26.06, for a total value of $234,540.00. Following the completion of the transaction, the director owned 19,839 shares in the company, valued at approximately $517,004.34. The trade was a 31.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 18,055 shares of company stock worth $456,061. Corporate insiders own 31.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in Doximity by 4.1% in the fourth quarter. Vanguard Group Inc. now owns 13,285,485 shares of the company’s stock worth $588,281,000 after acquiring an additional 518,916 shares in the last quarter. Aubrey Capital Management Ltd bought a new position in shares of Doximity in the third quarter valued at approximately $4,572,000. UBS Group AG lifted its holdings in shares of Doximity by 26.5% in the fourth quarter. UBS Group AG now owns 680,260 shares of the company’s stock valued at $30,122,000 after purchasing an additional 142,408 shares in the last quarter. Blair William & Co. IL lifted its holdings in shares of Doximity by 1,990.7% in the third quarter. Blair William & Co. IL now owns 362,740 shares of the company’s stock valued at $26,534,000 after purchasing an additional 345,390 shares in the last quarter. Finally, William Blair Investment Management LLC lifted its holdings in shares of Doximity by 11.7% in the third quarter. William Blair Investment Management LLC now owns 5,829,169 shares of the company’s stock valued at $426,404,000 after purchasing an additional 609,775 shares in the last quarter. Institutional investors own 87.19% of the company’s stock.

Key Stories Impacting Doximity

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Doximity said revenue still grew year over year, and its earnings call highlighted strong engagement from AI tool adoption, suggesting the platform is gaining traction with physicians. Doximity Stock Falls on Q4 Earnings Miss, Revenues Beat, Margins Down
• Positive Sentiment: Doximity announced a partnership with Aledade to bring clinical AI tools into value-based care workflows, which could support longer-term adoption and monetization. DOCS Teams Up With Aledade to Bring Clinical AI to Value-Based Care
• Neutral Sentiment: Several articles noted the stock has become technically oversold after a sharp selloff, which could set up a bounce if sentiment improves. Down 25.7% in 4 Weeks, Here’s Why Doximity (DOCS) Looks Ripe for a Turnaround
• Negative Sentiment: Doximity missed quarterly earnings estimates and issued fiscal 2027 revenue guidance below Wall Street expectations, raising concerns that growth is slowing. Doximity, Inc. (DOCS) Q4 2026 Earnings Call Transcript
• Negative Sentiment: Analysts turned more cautious, with multiple firms cutting price targets or downgrading the stock, including Baird, Wells Fargo, BTIG, JPMorgan, Mizuho, BMO, Needham and Truist. DOCS vs. HIMS: Which Stock Is the Better Value Option?
• Negative Sentiment: Investor caution also increased after insider selling was disclosed, even though it was tied to a pre-arranged 10b5-1 plan and tax withholding. Doximity (NYSE:DOCS) Insider Siddharth Sitaram Sells 2,309 Shares

About Doximity

Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.

The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.